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Comprehensive analysis of brain functiondepends onunderstanding thedynamics of diverse neural signalingprocesses over large tissue
volumes in intact animals and humans. Most existing approaches to measuring brain signaling suffer from limited tissue penetration,
poor resolution, or lackof specificity forwell-definedneural events.Herewediscuss anewbrain activitymappingmethod that overcomes
someof these problemsby combiningMRIwith contrast agents sensitive to neural signaling. The goal of this “molecular fMRI” approach
is to permit noninvasive whole-brain neuroimaging with specificity and resolution approaching current optical neuroimagingmethods.
In this article, we describe the context and need for molecular fMRI as well as the state of the technology today. We explain how major
types of MRI probes work and how they can be sensitized to neurobiological processes, such as neurotransmitter release, calcium
signaling, and gene expression changes.We comment both on past work in the field and on challenges and promising avenues for future
development.
Introduction
President Barack Obama established the Federal BRAIN Initia-
tive as a means to “accelerate the development and application of
new technologies that will enable researchers to produce dynamic
pictures of the brain that show how individual brain cells and
complex neural circuits interact at the speed of thought” (Barg-
mann et al., 2014). Although the President probably did not
mean the phrase “dynamic pictures” literally, there is an obvious
logic to his choice of visual language. Our species has used images
to express complex ideas for at least 20,000 years, and the special
potency of images as explanatory vehicles may indeed be hard-
wired into us. In the neuroscience of today, techniques that liter-
ally produce dynamic pictures of the brain — what is often called
functional imaging — are increasingly ascendant (Silva et al.,
2011; Chen et al., 2013; Rose et al., 2014; Hamel et al., 2015), and
they have a particularly important role to play in the continuing
exploration of what brains do and how they do it.
Few neurotechnologies have been more influential in recent
years than fMRI (Rosen and Savoy, 2012; Smith, 2012; Ug˘urbil,
2012). As practiced in most laboratories and clinics, fMRI in-
volves collecting a series of brain scans from a subject, approxi-
mately once a second, and then analyzing the scans for changes
from image to image that reflect dynamic brain activity. Because
MRI is completely noninvasive and visualizes tissue of any thick-
ness, entire brains or large parts of brains in humans or animals
can be studied at once. The signals detected by fMRI usually arise
from changes in blood flow (hemodynamics) triggered by neural
activity. MRI can be sensitized to these changes either by injecting
magnetically active molecules called contrast agents into the
bloodstream, as was done in the very first fMRI experiments
(Belliveau et al., 1991), or by choosing imaging conditions that
allow direct detection of intrinsic vascular changes. So-called
BOLD fMRI is performed under conditions sensitive to local
concentrations of deoxygenated blood, which is itself magneti-
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Significance Statement
Brain researchers currently have a choice between measuring neural activity using cellular-level recording techniques, such as
electrophysiology andoptical imaging, orwhole-brain imagingmethods, such as fMRI. Cellular levelmethods are precise but only
address a small portion of mammalian brains; on the other hand, whole-brain neuroimaging techniques provide very little
specificity for neural pathways or signaling components of interest. The molecular fMRI techniques we discuss have particular
potential to combine the specificity of cellular-level measurements with the noninvasive whole-brain coverage of fMRI. On the
other hand, molecular fMRI is only just getting off the ground. This article aims to offer a snapshot of the status and future
prospects for development of molecular fMRI techniques.
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cally active (Kim and Ogawa, 2012). BOLD fMRI is currently the
most common technique for human functional brain imaging
and is applied in thousands of studies each year.
Despite the popularity of mainstream fMRI methods, limita-
tions of these techniques have been widely recognized (Consta-
ble, 2006; Jasanoff, 2007; Logothetis, 2008; Glover, 2011).
Because brain activity mapping with fMRI depends on neurovas-
cular coupling, resolution at the level of single cells is out of reach.
Fundamental limitations on the spatial detail provided by hemo-
dynamic mechanisms may be set by the spacing between capillar-
ies in the brain,50 m. More importantly, the cellular origins
of functional imaging signals are obscured by the fact that many
different cells and cell types contribute simultaneously to the
observed fMRI data from each 3D volume element in the brain.
There is no way to ascertain what balance of excitation, inhibi-
tion, or neuromodulation gives rise to localized BOLD responses,
or to determine the input-output relationships among areas dis-
playing apparent activation. The temporal resolution of fMRI
techniques is also limited by the phenomenology of blood flow;
hemodynamic changes are usually delayed and broadened over a
period of several seconds, with respect to underlying neural sig-
naling processes. A final drawback of conventional fMRI meth-
ods is that the signal changes they detect are quite small. As a
result, statistical analysis of repeated trials or stimulus presenta-
tions is usually required, leaving the technique prone to false
positives and negatives (Bennett et al., 2009).
Together, the limitations of hemodynamic fMRI make it a
poor tool for dissecting neural function at the level of cells or
circuits, even as it remains the premier approach for mapping
spatial activity patterns in human subjects and most animals. Not
surprisingly, improving on current functional imaging methods
is therefore both a major goal and significant problem (Barg-
mann et al., 2014). Past attempts to address the limitations of
fMRI techniques have included empirical characterization of the
relationships between BOLD responses and cellular-level signals
detectable by electrophysiology or optical imaging (Logothetis et
al., 2001; Schulz et al., 2012), mechanistic dissection of the sig-
naling pathways that relate neural activity to hemodynamic
changes (Attwell et al., 2010; Hillman, 2014), and mapping of
fMRI responses to specific brain stimuli of molecular and cellular
origin (Chen et al., 1997; Tolias et al., 2005; Lee et al., 2010a; Desai
et al., 2011). Such approaches can facilitate interpretation of
functional imaging data, at least in some contexts, but do not
provide novel readouts. Functional imaging techniques with im-
proved specificity have been sought by sensitizing MRI acquisi-
tion schemes primarily to small blood vessels (Duong et al.,
2003), or by trying to tease apart the separate contributions of
blood flow, volume, and oxygenation changes to hemodynamic
responses using methods, such as “calibrated fMRI” (Hoge,
2012). More radical fMRI approaches have tried to resolve
endogenous activity-dependent brain signals arising from
nonhemodynamic sources, such as diffusion changes (Le Bihan,
2007), neuronal magnetic fields (Bandettini et al., 2005), and
metabolite-dependent spectroscopic signals (Mangia et al., 2009;
Hyder and Rothman, 2012). An advantage of such methods is
that they can be applied in humans or animals without the need
for invasive procedures, but a disadvantage is that most endoge-
nous signals are even smaller than hemodynamic fMRI effects
and are therefore difficult to discern unambiguously. There is
therefore a persistent need for more robust and mechanistically
interpretable approaches to functional brain imaging.
Molecular fMRI
An ideal next-generation functional imaging method would be
one that could combine the noninvasive whole brain coverage of
fMRI with the resolution and molecular specificity achieved by
optical functional imaging techniques. Modern optical imaging
provides cellular level readouts of neural activity (Hamel et al.,
2015). These approaches can penetrate deep into tissue with the
aid of multiphoton fluorescence excitation, endoscopy systems,
and prisms, although with limited fields of view. For certain small
transparent organisms, optical functional imaging can measure
every neuron in the brain, with frame rates of 1 Hz or better
(Ahrens et al., 2013; Schro¨del et al., 2013). At the core of success-
ful optical neuroimaging methods are synthetic and protein-
based fluorescent indicators descended from probes first
introduced in the 1980s and 1990s (Rose et al., 2014). In the quest
to establish next-generation noninvasive imaging techniques, the
development of analogous probes detectable by MRI, together
with corresponding delivery and readout methods, is of para-
mount importance. Such probes would enable “molecular
fMRI,” a hybrid of molecular imaging with fMRI in which tar-
geted molecular probe-mediated readouts form the basis for
functional brain imaging. Molecular fMRI could eventually en-
able noninvasive functional neuroimaging with molecular spec-
ificity to be performed across multiple brain regions in animals
ranging from rodents to nonhuman primates, and perhaps even
eventually people, but the technology is still in its nascency. The
purpose of this Techsights article is to introduce the reader to
emerging molecular fMRI methods and to comment on some of
the future directions and challenges of this evolving research area.
An early form of molecular fMRI was introduced by Alan
Koretsky’s laboratory in the late 1990s (Lin and Koretsky, 1997).
The studies used manganese ions (Mn 2) to label neural popu-
lations activated by stimuli during or before imaging. Mn 2 en-
ters depolarized cells through voltage-gated calcium channels
and accumulates over time. Because Mn 2 is paramagnetic, it
acts as an MRI contrast agent and can be visualized by imaging.
Generating sufficient Mn 2-based contrast for activity labeling
generally requires stimulation over minutes to hours (Massaad
and Pautler, 2011) but can occasionally result in signal enhance-
ments of 100% (Lin and Koretsky, 1997). The resulting con-
trast patterns spread to some extent between cells and return to
baseline over days, limiting both the specificity of labeling and the
possibilities for truly dynamic functional imaging. On the other
hand, the technique offers advantages in that it is very easy to
implement and that Mn 2 labeling can take place in freely be-
having animals before imaging, which requires immobilization
(Pautler, 2006).
The first true molecular fMRI study with temporal resolution
approaching the speed of thought was published recently by our
group using an MRI contrast agent sensitive to the neurotrans-
mitter dopamine (Lee et al., 2014). The probe is a magnetically
active metalloprotein, similar to hemoglobin in the blood, that
was engineered to bind dopamine selectively with a dissociation
constant of1M (Fig. 1A). To map dopaminergic brain activity
using this MRI sensor, we injected it directly into rat brains and
acquired serial images with a frame rate of 0.13 Hz during inter-
mittent delivery of electrical stimuli to a neural fiber tract called
the medial forebrain bundle (Fig. 1B). Across fields of view cor-
responding to the probe distribution volume of 50 l, we ob-
served maximal signal changes on the order of 1%–3%, similar to
typical BOLD response magnitudes, corresponding to stimulus-
evoked extracellular dopamine concentrations from 8 to 24 M.
Contributions from probe-independent physiological changes
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were ruled out using control experiments with a dopamine-
insensitive probe. Dopamine imaging results resemble a standard
fMRI activation map but denote quantitative measures of an in-
dividual signaling molecule, rather than the generic neurovascu-
lar changes reflected in BOLD contrast (Fig. 1C). Data reveal a
pattern of dopamine release that peaks in the core of the nucleus
accumbens, probably reflecting dependence on the reward stim-
ulation site optimized for robust operant behavior in the im-
planted rats.
The dopamine imaging study represents a landmark in the
development of molecular fMRI. Even in its current crude and
relatively insensitive form, the technique offers spatial and tem-
poral resolution far in excess of the previous state-of-the-art do-
pamine functional imaging methods based on PET (Laruelle et
al., 1997; Laruelle, 2000). Further room for improvement is there
as well: the theoretical resolution limit of MRI is 10 m, and
some previous functional imaging studies have been performed
with a combination of 0.05l voxel volume and 20 Hz frame rate
(Yu et al., 2014). With advances in molecular probe technology,
one could imagine a future in which molecular fMRI is used to
determine brain-wide neurochemical maps corresponding to a
universe of stimuli and behavioral programs. In animals and
eventually people, such methods might provide fundamental in-
sights into the relationships between neurotransmitter release
patterns and cognitive phenomena, affective states, and diseases,
with resolution perhaps approaching the level of individual cells.
One can also imagine variants of the tech-
nique that sense other transmitters, such
as glutamate, GABA, and glycine, as well
as major intracellular signaling molecules,
such as calcium ions, cyclic adenosine
monophosphate, and inositol triphos-
phate, vastly increasing the number of po-
tential biomarkers for both basic scientific
and clinical studies. In short, there could
be noninvasive MRI-based analogs for
each of the most powerful optical neuro-
imaging approaches currently available to
researchers.
But the technological hurdles on the
way to realizing this vision are almost as
significant as the potential rewards (Lely-
veld et al., 2011). There are several areas
where improvements are necessary: Most
obviously, more effective and minimally
invasive methods for delivering imaging
agents to large brain volumes must be
sought. For imaging of intracellular tar-
gets, developing probes that permeate
cells and localize cytosolically is impor-
tant (Zhang et al., 2007; Lee et al., 2010b),
and for eventual applicability of molecu-
lar fMRI in people, finding a way to get
contrast agents across the blood– brain
barrier (BBB) will also be essential. In ad-
dition, probes that provide better sensitiv-
ity to molecular targets in the brain must
be developed. Most signaling molecules
are present at nanomolar concentrations
in tissue, but the existing molecular fMRI
sensors must be present at micromolar
levels to provide detectable signal changes
(Lelyveld et al., 2011). This increases the
requirements for effective probe delivery, allows only very high
levels of neurotransmitter to be detected, and raises the chances
that the probes interfere with the very signaling pathways they are
designed to measure.
The development of improved probes with submicromolar
sensitivity to analytes is the single most significant frontier in the
further development of molecular fMRI. What are the best strat-
egies by which to accomplish this? To consider the possible routes
forward, we need to dive into the physics and chemistry of MRI
molecular imaging agents. In the next sections, we briefly de-
scribe the properties of major classes of MRI agents, and we then
incorporate this information into a discussion of current and
future paths for the development of molecular fMRI.
Overview of MRImolecular imaging agents
MRI is based on the absorption of radio waves by certain types of
atomic nuclei. Protons in water are the most abundant such nu-
clei, and standard MRI experiments in effect map the distribution
of water throughout the body (Nishimura, 1996). MRI signals are
also affected by so-called longitudinal and transverse relaxation
times,T1 andT2, respectively. Roughly speaking, the shorterT1 is,
the more frequently an MRI signal can be measured and the
brighter an image will be. The shorterT2 is, the more fleeting each
MRI signal is and the darker an image will be. Most hemody-
namic fMRI is based on T2 alterations induced by changes in
hemoglobin oxygenation (Kwong et al., 1992; Ogawa et al.,
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Figure1. Molecular fMRIwith a probe sensitive to dopamine.A, Structure of the dopamine-sensitive contrast agent BM3h-9D7
(Brustad et al., 2012), showing the paramagnetic heme group that createsMRI contrast effects. Binding of dopamine (blue) to the
heme blocks interactions with water molecules (red), turning off the contrast agent by decreasing its r1 value. B, Average time
course of molecular fMRI signal changes (green) observed in rat ventral striatum during brain stimulation known to evoke dopa-
mine release (red line), in the presence of BM3h-9D7 (Lee et al., 2014). A control time course (gray) was obtained using the same
experimental procedure in conjunction with a probe variant insensitive to dopamine, BM3h-WT. Error bars indicate SEM across 7
animals each. Inset, Coronal slice througha rat brain (bregma0.7mm), indicating injection cannula placement (arrowhead) and
the area of injection (green circle). C, Map of peak dopamine concentrations (red-yellow) evoked by reward-related stimulation in
three slices through ventral striatum. Yellow represents rostrocaudal coordinates. White represents brain atlas. Green outline
indicates area of contrast agent coverage. Gray underlay is an anatomical image. A, Adapted from Brustad et al. (2012). B, C,
Adapted from Lee et al. (2014).
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1992), and additional hemodynamic techniques rely on T1-
related effects caused by changes in blood flow (Detre et al.,
1992). MRI molecular imaging agents also work by interacting
with water molecules to alter T1 and T2, or in some cases by
incorporating nuclei that can be probed using radio frequencies
distinct from those used to measure water protons.
The first MRI contrast agents, and the most widely used to this
day, are small-molecule chelates that incorporate paramagnetic
ions like gadolinium (Gd 3) or manganese (Mn 2 or Mn 3)
(Lauffer, 1987). Paramagnetic complexes like this are best known
for their ability to shorten T1 relaxation, and they are usually
called T1 agents (Fig. 2A). The magnitude of their effects is quan-
tified by a magnetic field-dependent parameter called the T1 re-
laxivity (r1). Gadolinium diethylenetriamine pentaacetic acid
(Gd-DTPA) and gadolinium 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (Gd-DOTA) are prototypical T1 agents,
with relaxivity values of 3–5 mM1 s1 at moderate to high clin-
ical MRI field strengths (3–7 T) (Kalavagunta et al., 2014; Shen et
al., 2015). T1 agents usually need to be present at concentrations
10 M to be detected, although theoretical studies predict that
considerable further improvements in sensitivity might even-
tually be possible (Caravan et al., 2009). Relaxivity values of
paramagnetic chelators depend on a number of molecular pa-
rameters, most prominently including the spin number of the
paramagnetic species, its solvent interaction characteristics,
and its rate of tumbling in solution (Merbach et al., 2013).
These parameters can be modulated when a contrast agent
interacts with another molecule, forming the basis of a sensing
mechanism.
Magnetic nanoparticles constitute another widely used type of
contrast agent (Fig. 2B) (Laurent et al., 2013). Typical magnetic
nanoparticles consist of a highly magnetizeable core, usually
composed of iron oxide or a related superparamagnetic mineral,
surrounded by a layer of hydrophilic molecules that renders the
nanoparticle water soluble (Rodriguez et al., 2014). Nanoparticle
agents are best known for shortening T2 values and darkening
T2-weighted MRI scans. The influence of these agents is indicated
by their T2 relaxivity (r2), which depends most prominently on
the size of the particle and the thickness of its coating. Magnetic
nanoparticles often have r2 values100 (mM metal)
1 s1, and
can be detected at metal concentrations 10 M; because there
are typically1000 metal atoms per nanoparticle core, this trans-
lates into particle concentrations 10 nM. Effective changes in
nanoparticle size and therefore r2 can be produced by inducing
particle clustering (Perez et al., 2002), and this has formed the
basis of several nanoparticle-based MRI sensors. The drawback of
this approach is that clustering is a relatively slow and uncon-
trolled molecular mechanism (Shapiro et al., 2006).
Diamagnetic molecules have been increasingly used as MRI
imaging agents in recent years. A key advantage of diamagnetic
molecular MRI agents over paramagnetic chelates and nanopar-
ticles is that they tend to be more biocompatible, and that in some
cases endogenous molecules be used (Liu et al., 2013). Molecules
suitable for such applications absorb radio waves at characteristic
frequencies, a bit like optical dyes, allowing them to be probed
directly by MRI hardware and visualized as distinct “colors.”
Normally, such species are too dilute to be measured robustly by
MRI, but two techniques have been used to boost the sensitivity
of their detection. In a first approach, the MRI signals from dia-
magnetic molecules are boosted artificially, sometimes by factors
of10 4, using so-called hyperpolarization techniques (Taratula
and Dmochowski, 2010; Meier et al., 2014). The substances can
then be injected into or in some cases inhaled by the subject and
imaged before effects of the hyperpolarization fade away, usually
within seconds to minutes. In the second approach, called chem-
ical exchange saturation transfer (CEST) (Fig. 2C), the effects of
radiofrequency absorbance by a diamagnetic agent are amplified
by a rapid process of physical exchange between atoms on the
agent and a much larger pool of atoms in the surrounding solvent
(Ward et al., 2000). This allows MRI to visualize CEST agents at
concentrations typically in the millimolar range (van Zijl and
Yadav, 2011).
Genetically encoded biomolecular MRI probes represent what
may be considered a fourth class of molecular imaging agents,
although in each case they work by one or more of the mecha-
nisms discussed above but warrant special consideration because
of their potential for truly noninvasive endogenous production
of probes in animals. Paramagnetic metalloproteins are the
nearest biosynthetic equivalent to T1 and T2 contrast agents
(Matsumoto and Jasanoff, 2013). Both natural and engineered
metalloproteins have been harnessed to act as MRI sensors. Most
metalloproteins contain a small number of bound metal ions and
display characteristics similar to T1 agents. An exception is the
protein ferritin, which forms a roughly spherical shell of 24
O
O
O
O
N
N
N
O
O
O
O
O
O
HH O
Gd
H
H
O
H
H
O
H HO
H
H
O
A
paramagnetic
usually low MW
µM sensitivity
unimolecular sensing
B
(super)paramagnetic
usually nanoparticulate
nM sensitivity
cluster-based sensing
N
H
NH2
HO
COOH
C
H
H
O
H HO H
H
O
usually diamagnetic
low or high MW
µM-mM sensitivity
“multicolor imaging”
T1 contrast agent T2 contrast agent CEST agent
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protein subunits surrounding a small mineral core of weakly
magnetic hydrated iron oxide. This enables ferritin to function as
a protein-based magnetic nanoparticle, but with relaxivity much
lower than synthetic analogs (Gillis and Koenig, 1987; Gossuin et
al., 2002). Biosynthetic magnetic nanoparticles called magneto-
somes are also formed by so-called magnetotactic bacteria
(Schu¨ler, 2007). Magnetosomes are actually tiny organelles, com-
posed of protein elements in a lipid membrane that surrounds a
superparamagnetic core similar to synthetic magnetic nanopar-
ticles. Engineered proteins and peptides have also been shown to
act as diamagnetic CEST agents detectable by MRI. In some cases,
these species have addressed the intrinsic sensitivity limitations of
CEST contrast by combining many monomeric CEST agents into
a single biopolymer (Bar-Shir et al., 2015).
Future development of molecular fMRI will depend on effec-
tive application of MRI probe architectures to the measurement
of well-defined signaling events in the brain. In the next sections,
we will discuss past efforts and future prospects for using MRI
probes to target three types of dynamic neural signals: neu-
rotransmitter release, intracellular calcium ions, and gene expres-
sion changes.
Neurotransmitter-sensitive MRI contrast agents
One of the most obvious ways to measure functionally specific
information from the brain is to use imaging agents to target
individual neurotransmitters, several of which play relatively de-
fined roles in neural processing. A number of molecular MRI
strategies have been introduced to accomplish this. The dopa-
mine imaging agent used in the Lee et al. (2014) molecular fMRI
study is an engineered protein based on a cytochrome P450 heme
domain, BM3h; variants of the same protein have also been pro-
duced for molecular imaging of serotonin and norepinephrine
(Brustad et al., 2012). These contrast agents act as T1 agents with
relaxivities of1 mM1 s1, and they can detect neurotransmit-
ters at low micromolar concentrations (Shapiro et al., 2010).
Additional T1 contrast agents have been developed to target
amino acid transmitters. Oukhatar et al. (2015) synthesized a
complex that combines a crown ether cation-binding motif with
a gadolinium chelator capable of coordinating an additional car-
boxylate moiety. The resulting complexes displayed millimolar
affinity for glutamate, GABA, and glycine, and neurotransmitter
binding was accompanied by r1 changes of up to 81% in buffer.
Another T1 agent synthesized by Mishra et al. (2013) was de-
signed to sense glutamate by a mechanism involving competitive
binding to mGluR5 receptors, somewhat like receptor displace-
ment approaches used for PET (Laruelle, 2000). This probe
bound to mGluR5-expressing cells in culture and produced MRI-
detectable T1 changes at micromolar concentrations in vitro. In
another indirect approach, our laboratory used a zinc-sensitive
MRI agent to label cells that corelease zinc ions with glutamate at
synapses (Lee et al., 2010b). We observed approximately twofold
more pronounced staining of neural tissue when we injected this
probe into the hippocampus, where zinc functions as a glutamate
cotransmitter, than into the striatum, which contains little extra-
cellular zinc.
The only MRI-based neurotransmitter imaging method that
has so far been demonstrated in human subjects is the probe-
independent approach of using endogenous glutamate itself for
detection by CEST MRI (Cai et al., 2012). A relatively specific
CEST signal can be obtained using radio irradiation at a fre-
quency corresponding to the exchangeable amine protons of glu-
tamate. The approach was recently applied in a small study of
epileptic patients among which an excess CEST signal of 1%
correlated with lateralized temporal lobe seizure foci (Davis et al.,
2015). Mechanistic interpretation of these results is complicated
by the fact that glutamate-dependent CEST signals are contami-
nated by pH effects and other metabolites, and also because the
approach does not differentiate between extracellular and intra-
cellular glutamate concentrations. The fact that the CEST con-
trast in this approach arises entirely from endogenous factors
makes it difficult to design controls for ruling out glutamate-
independent sources. Nevertheless, evidence from in vivo gluta-
mate magnetic resonance spectroscopy studies suggests that
dynamic brain activation-related changes in glutamate signals
could in principle be detectable at relatively low resolution and
on a timescale of minutes (Bednarˇík et al., 2015).
Although neurotransmitter-sensitive molecular fMRI tech-
niques can yield useful information under some conditions, the
current methods come up short against the capabilities one
would ideally want. Neurotransmitter concentrations in the
brain vary widely in concentration and dynamics but are mostly
out of range of current imaging strategies. Resting interstitial
dopamine levels are generally 0.1 M and during naturalistic
behavior can fluctuate to levels up to 1–2 M on time scales
approximately one-tenth of a second (Taylor et al., 2015) (com-
pare detection limit of 2 M dopamine with 8 s acquisition for
BM3h-based agents) (Lee et al., 2014). Basal parenchymal gluta-
mate and GABA concentrations are similar to dopamine but tend
to fluctuate on a much faster time scale, with peak concentrations
that rarely exceed 1 M (Slaney et al., 2012). An MRI probe well
suited to detecting these kinds of dynamics should ideally be
present at concentrations below the mid-nanomolar range, a reg-
imen that is currently most accessible to nanoparticle-based con-
trast agents. A task for molecular engineers should therefore be to
construct neurotransmitter sensors that escape some of the tra-
ditional limitations of nanoparticle-based probes, such as slow
transport and response kinetics (Rodriguez et al., 2014). Delivery
of such agents to the brain will also be challenging, but noninva-
sive brain delivery methods are more feasible for sensors that
work at lower concentrations (Lelyveld et al., 2011).
MRI probes for calcium signaling
Intracellular calcium concentrations are currently the favored
target for functional neuroimaging using optical methods, and
for good reason. Cytosolic Ca 2 fluctuations extend from basal
concentrations near 0.1 M to levels as high as 10 M near syn-
apses and are already so heavily buffered in cells that addition of
calcium indicators produces minimal perturbation of calcium-
mediated signaling processes (Meldolesi, 2002). Powerful small
molecule fluorescent sensors for calcium have been available
since the 1980s (Grynkiewicz et al., 1985; Tsien et al., 1985); and
after many successive stages of refinement, genetically encoded
GFP-based calcium indicators descended from those introduced
in the late 1990s are now also in wide use (Miyawaki et al., 1997;
Nagai et al., 2001; Rose et al., 2014). Given this precedent, the
development of calcium-dependent molecular fMRI methods is
an obvious priority.
Several groups have worked on calcium imaging approaches
for MRI using different strategies, but these have not yet proved
successful molecular fMRI. The activity-dependent manganese
labeling methods of Koretsky and colleagues provide a calcium-
related MRI readout, but for biokinetic reasons discussed above,
cannot achieve real-time imaging (Lin and Koretsky, 1997; Inoue
et al., 2011). The first T1-based small molecule calcium sensor
was a compound called Gd-DOPTA, reported15 years ago by
Li et al. (2002). This agent is a small BAPTA-based gadolinium
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complex that responds to Ca 2 increases near an EC50 of 1 M
with an r1 change from 3.3 to 5.8 mM
1 s1 at a field of 11.7 T. In
principle, this agent should be close to ideal for intracellular cal-
cium ion imaging, but its delivery into cells could be complicated
by the highly polar nature of the Gd 3 chelating groups it con-
tains. Future applications of these kinds of compounds could
follow either from combining the compounds with cell delivery
strategies (Bhorade et al., 2000; Hung et al., 2014) or by synthe-
sizing contrast agents from building blocks that are themselves
cell permeable (Zhang et al., 2007; Lee et al., 2010b).
Angelovski and colleagues (Angelovski et al., 2008; Dhingra et
al., 2008) have sought to avoid the need for intracellular delivery
by producing compounds similar to Gd-DOPTA, but tuned to
detect extracellular calcium changes in the brain. This bypasses
the requirement for membrane permeability but targets a phe-
nomenon of less direct association with neural activity. These
authors have generated a series of calcium probes with affinities
in the mid-micromolar to millimolar range, including molecules
that work by both relaxation-based and spectroscopic mecha-
nisms (Angelovski et al., 2011; Kadjane et al., 2014). Several of
these probes involve fusion of Gd-DOTA-based macrocyclic
complexes to the calcium chelator EGTA. In recent work, one
such complex was fused to a diamagnetic polysiloxane nanopar-
ticle platform to produce slow-clearing contrast agents that dis-
play r1 changes from 3.6 to 7.0 mM
1 s1 upon calcium binding
with a Kd of 1.9 mM (Moussaron et al., 2015). The authors in-
jected these agents intravenously in mice, either with or without a
subsequent injection of intravascular CaCl2 solution. They found
30% average T1-weighted contrast enhancement differences in
the kidney, contingent on the CaCl2; this was the first time cal-
cium responses have been demonstrated using an MRI calcium
sensor in vivo, albeit not yet in the brain.
Our own group has introduced highly sensitive nanoparticle-
based calcium probes that produce more than threefold changes
in T2 upon calcium binding in buffer (Atanasijevic et al., 2006).
This permits detection of Ca 2 ions with a binding midpoint of
1.4 M at nanosensor concentrations1 nM (90 M total Fe). A
drawback of the prototype sensor was its large size and slow mul-
timolecular response mechanism, which depends on reversible
nanoparticle clustering (Perez et al., 2002; Shapiro et al., 2006). In
a second-generation calcium nanosensor, however, we were able
to demonstrate sensor responses that take place within seconds
by using smaller nanoparticles (Rodriguez et al., 2014). An obvi-
ous problem with nanoparticle-based MRI sensors for intracel-
lular Ca 2 is again the difficulty of delivering them to the brain
and into cells. An intriguing direction for future development of
this approach is to try to genetically encode the entire sensor,
producing nanoparticle components inside cells in the form of
engineered ferritin-based proteins. The same clustering mecha-
nism that actuates synthetic nanoparticle sensors can be imple-
mented using ferritin (Bennett et al., 2008; Shapiro et al., 2009).
We recently showed that clustering of genetically expressed fer-
ritin fusion proteins can be induced inside cells and also produces
MRI-detectable T2 changes (Matsumoto et al., 2015); this consti-
tutes a key proof of concept for intracellular ferritin-based sensor
strategies.
MRI reporters of gene expression in the brain
Gene reporters are not the most obvious tools for functional
brain imaging, and current reporter technologies certainly can-
not operate at the speed of thought. But the utility of techniques
such as c-Fos immunohistochemistry and more recent improved
equivalents (Barth, 2007; Kova´cs, 2008) nevertheless provides
inspiration for the possibility of using MRI-detectable genetic
reporters as tools for neural activity mapping by noninvasive
imaging (Jasanoff, 2005). Genetic reporters for MRI could also be
useful for monitoring plasticity or development. Although the
spatial resolution of MRI readouts is far worse than the histo-
chemical techniques used to detect immediate early gene activa-
tion optically, the key advantage of MRI is the potential to image
repeatedly in individual animals, either to compare responses
among different conditions or to perform longitudinal studies.
An added benefit with respect to hemodynamic or molecular
fMRI could be the possibility of performing gene induction ex-
periments in awake, behaving animals, rather than in the restric-
tive environment of the scanner.
More than 20 specific molecular mechanisms for MRI-based
detection of reporter gene expression have been proposed (Sriv-
astava et al., 2015). Many of these require the interaction between
a reporter gene product and a contrast agent substrate or ligand.
Ideally, an MRI reporter would avoid the use of a cofactor, both
because of the added complexity this introduces and because of
the potential difficulty of delivering of the cofactor adequately to
the brain. The simplest MRI reporter gene detection methods
involve the expression of a single protein, which may be incorpo-
rated into transgenic or virally transduced animals. In this light, a
handful of MRI reporter genes deserve special mention.
The family of MRI reporter genes that has been most widely
explored to date are the ferritins. Papers from the laboratories of
Eric Ahrens and Michal Neeman first demonstrated that human
ferritin overexpression in cultured cells and small animals could
lead to discernible MRI contrast changes, including in brain
(Cohen et al., 2005, 2007; Genove et al., 2005). Protein engineer-
ing has produced ferritins that show improved detectability (Ior-
danova et al., 2010; Matsumoto et al., 2015). Currently available
ferritin reporters still appear to be unreliable in vivo, however
(Bernau et al., 2015; Pereira et al., 2015). Further efforts to im-
prove the magnetization and iron content of ferritins may there-
fore be critical to transforming these proteins into truly robust
reporters for MRI molecular imaging (Matsumoto et al., 2015).
Another approach to generating metal-dependent contrast has
been to use metal ion transporters as MRI reporters. Because of
their enzymatic action, metal transporters could be more effec-
tive than ferritins at promoting cellular metal accumulation and
consequent MRI contrast (Goldhawk et al., 2009; Paproski et al.,
2011; Bartelle et al., 2013). The most promising results to date in
brain have come from overexpression of the divalent metal trans-
porter DMT1, in combination with injection of substrate man-
ganese ions, which can be injected peripherally (Bartelle et al.,
2013). These studies showed that in vivo transduction of neonatal
mouse brain regions with the DMT1 gene gives rise to selective
manganese-enhanced T1 changes by up to 26%.
For MRI-based detection of gene expression, genetically en-
coded diamagnetic CEST reporters have special advantages.
These proteins do not induce cellular metal accumulation or in-
teract with homeostatic processes, and they are therefore less
likely to be toxic than ferritins or metal transporters. In addition,
the fact that CEST reporters become MRI-visible immediately
upon biosynthesis could make these proteins better suited to
time-resolved studies of gene regulation. The first reporter gene
detectable by CEST imaging was an artificial lysine-rich protein,
engineered to combat sensitivity limitations of CEST contrast by
including a particularly high number of equivalent exchangeable
protons (Gilad et al., 2007). The authors showed that implanted
cells overexpressing this protein give rise to an 5% change in
image signal with respect to controls in brain. Although CEST-
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like contrast can arise from endogenous sources, the authors
compared their construct with a control expression vector to rule
out such nonspecific effects. Further improvements to CEST-
based genetic reporters have been possible by screening peptide
sequences and alternative protein platforms for enhanced CEST
contrast (Bar-Shir et al., 2015). If further sensitivity gains are
forthcoming, diamagnetic CEST reporters could offer unique po-
tential for noninvasive activity-dependent reporter gene map-
ping with minimal disruption to neural systems.
In conclusion, molecular fMRI is a new experimental ap-
proach that combines noninvasive whole-brain imaging with
molecular probe-mediated readouts of specific mechanistic
components of brain function. In the past several years, there
have been important demonstrations of the feasibility of mo-
lecular fMRI-based mapping of neural activity and related
phenomena in the brain (Table 1). The technology is still ru-
dimentary, but there are a number of promising directions for
future research, in particular involving the development of
improved chemical and genetic MRI contrast agents for imag-
ing neurotransmitters, calcium ions, and gene expression, as
well as probes that detect previously unaddressed neurophys-
iological parameters, such as membrane potential. The over-
arching need is for imaging agents that offer better sensitivity
than currently available, and for effective strategies to deliver
these probes to their sites of action in cells or brain tissue.
Advances in these two areas will be critical to the potential use
of molecular fMRI methods in human subjects.
An ideal combination of nanomolar sensitivity, subsecond
response times, and BBB permeability might best be realized
by combining high relaxivity T1 or T2 agents with minimally
invasive brain delivery strategies, such as receptor-mediated
trans-BBB transport (Pardridge, 2015). This will require sub-
stantial further molecular engineering of existing probe build-
ing blocks, or perhaps as an alternative, the introduction
of entirely new principles for operation of molecular fMRI
probes. For applications in animals, brain delivery using in-
tracranial injection or BBB disruption strategies could be ac-
ceptable in place of completely noninvasive strategies (Kroll
and Neuwelt, 1998; Vykhodtseva et al., 2008). As new probes
become available, it will be important to perform rigorous
validation studies. It is critical in each case to rule out alterna-
tive probe-independent explanations for apparent molecular
fMRI signal changes, such as endogenous changes in T1 or T2
relaxation rates or side effects of probe injection; in some
cases, mislocalization or inactivation of probes might pose
an additional complication. These factors can generally be
controlled for by performing experiments with analyte-
insensitive probe variants (as in Fig. 1B) and by comparing
molecular fMRI data with independent measurements of the
same biological targets (e.g., using optical imaging or electro-
chemistry) (Lee et al., 2014). In some cases, future validation and
use of molecular fMRI techniques may also benefit from suppression
of probe-independent endogenous MRI signals, for instance by us-
ing pharmacological techniques to reduce hemodynamic effects
(Bruhn et al., 2001; Stefanovic et al., 2006, 2007).
To realize the full potential of molecular fMRI, improve-
ments in probe technology must also be accompanied by
improvements in hardware. For instance, improved spa-
tiotemporal resolution is possible by combining multiple MRI
detection circuits for so-called parallel imaging, but this ap-
proach has yet to be applied to full extent for small animal
imaging (Feinberg and Setsompop, 2013). Cellular resolution
(20 m) molecular fMRI can probably eventually be
achieved but will likely depend also on access to MRI scanners
operating at 20 T, which are not yet routinely available; a
theoretical ceiling of 2 m on resolution arises from the
dependence of proton MRI on the diffusion of water mole-
cules (Callaghan, 1993). Unprecedented molecular-level brain
mapping experiments are already possible using today’s scan-
ners and imaging probes, however, suggesting that the con-
tinuing development of molecular fMRI technology will
remain a rewarding direction for our field.
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